StockData

CytomX Therapeutics vs Whitehawk Therapeutics

CTMX and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CTMX and WHWK compare

CytomX Therapeutics is the larger company, worth 2.4 times as much as Whitehawk Therapeutics ($423M against $176M).

CytomX Therapeutics grew revenue faster over the last twelve months (−87.0% versus −100% for Whitehawk Therapeutics).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCTMXWHWK
Size and price
Market cap$423M$176M
Share price$1.94$3.08
Change, 1 year−50.0%43.9%
Change, 5 years−71.3%−86.3%
Beta (5Y)1.552.33
Employees6923
StockData Score
Total score88
Valuation score11
Growth score1 (better)0
Performance score11
Health score56 (better)
Dividend score00
Valuation
P/S23.1×–
P/B1.4×1.0× (better)
FCF yield−19.5% (better)−39.5%
Growth
Revenue growth (TTM)−87.0% (better)−100%
Revenue growth, 5Y average2.2% (better)−12.6%
Net income growth (TTM)−266%–
EPS growth (TTM)−179%–
Profitability
Operating margin−476%–
Net margin−435%–
FCF margin−451%–
Return on equity−37.8% (better)−45.0%
Financial health
Debt / equity0.000.00
Current ratio9.3617.38 (better)
Altman Z-score0.796.35 (better)
Piotroski F-score24 (better)
Dividends and buybacks
Buyback yield−57.9%–
Shareholder yield−57.9%0.00% (better)
Ownership
Held by institutions97.9%75.8%
Held by insiders1.5%49.9%
Insider net buying, 12 months−$1.2M (better)−$2.6M
Short interest, % of float21.1%8.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.